{"id":"https://openalex.org/W3146777203","doi":null,"title":"IMPACT OF PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES ON RISK OF INCIDENT SYMPTOMATIC THROMBOEMBOLISM IN CHILDREN","display_name":"IMPACT OF PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES ON RISK OF INCIDENT SYMPTOMATIC THROMBOEMBOLISM IN CHILDREN","publication_year":2013,"publication_date":"2013-01-01","ids":{"openalex":"https://openalex.org/W3146777203","mag":"3146777203"},"language":"en","primary_location":{"id":"mag:3146777203","doi":null,"is_oa":false,"landing_page_url":"http://thd.org.tr/thdData/Books/703/impact-of-persistent-anti-phospholipid-antibodies-on-risk-of-incident-symptomati.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069337753","display_name":"Hale \u00d6ren","orcid":"https://orcid.org/0000-0001-5760-8007","observed_orcids":["https://orcid.org/0000-0001-5760-8007"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Hale \u00d6ren","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5760-8007","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5069337753"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10308","display_name":"Systemic Lupus Erythematosus Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10308","display_name":"Systemic Lupus Erythematosus Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10697","display_name":"Vasculitis and related conditions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antiphospholipid-antibodies","display_name":"antiphospholipid antibodies","score":0.9879999756813049},{"id":"https://openalex.org/keywords/lupus-anticoagulant","display_name":"lupus anticoagulant","score":0.8510000109672546},{"id":"https://openalex.org/keywords/antiphospholipid-syndrome","display_name":"antiphospholipid syndrome","score":0.8579999804496765},{"id":"https://openalex.org/keywords/thromboembolism","display_name":"thromboembolism","score":0.9190000295639038},{"id":"https://openalex.org/keywords/children","display_name":"children","score":0.7269999980926514},{"id":"https://openalex.org/keywords/thrombotic-risk","display_name":"thrombosis risk","score":0.7129999995231628},{"id":"https://openalex.org/keywords/anti-beta2-glycoprotein-i-antibodies","display_name":"anti-beta2-glycoprotein I antibodies","score":0.8500000238418579},{"id":"https://openalex.org/keywords/anticardiolipin-antibodies","display_name":"anticardiolipin antibodies","score":0.9919999837875366},{"id":"https://openalex.org/keywords/preoperative-testing","display_name":"preoperative screening","score":0.6980000138282776},{"id":"https://openalex.org/keywords/autoimmune-disease","display_name":"autoimmune disease","score":0.5400000214576721}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8548191785812378},{"id":"https://openalex.org/C2780868729","wikidata":"https://www.wikidata.org/wiki/Q261327","display_name":"Thrombosis","level":2,"score":0.6666377186775208},{"id":"https://openalex.org/C2776874634","wikidata":"https://www.wikidata.org/wiki/Q582207","display_name":"Antiphospholipid syndrome","level":3,"score":0.6595122218132019},{"id":"https://openalex.org/C2780022809","wikidata":"https://www.wikidata.org/wiki/Q5786759","display_name":"Lupus anticoagulant","level":3,"score":0.6364228129386902},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.6036799550056458},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5186204314231873},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4608919024467468},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4383491277694702},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35669195652008057},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3146777203","doi":null,"is_oa":false,"landing_page_url":"http://thd.org.tr/thdData/Books/703/impact-of-persistent-anti-phospholipid-antibodies-on-risk-of-incident-symptomati.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1975074770","https://openalex.org/W1998397662","https://openalex.org/W2008511586","https://openalex.org/W2023929943","https://openalex.org/W2032162517","https://openalex.org/W2038920352","https://openalex.org/W2054330426","https://openalex.org/W2071075889","https://openalex.org/W2121214216","https://openalex.org/W2129952144","https://openalex.org/W2132769675","https://openalex.org/W2134148711","https://openalex.org/W2156967456","https://openalex.org/W2172031337"],"related_works":["https://openalex.org/W2184542765","https://openalex.org/W3082930766","https://openalex.org/W7223123384","https://openalex.org/W7096389688","https://openalex.org/W1984657210","https://openalex.org/W2182389841","https://openalex.org/W1977157162","https://openalex.org/W2140529924","https://openalex.org/W2065156106","https://openalex.org/W2519454240"],"abstract_inverted_index":{"The":[0,150],"anti-phospholipid":[1],"antibodies":[2,39,155],"(aPLA)":[3],"are":[4,40,51],"immunglobulins":[5],"(IgG,":[6],"IgM,":[7],"and":[8,13,35,54,86,142],"IgA)":[9],"directed":[10],"against":[11],"phospholipids":[12],"phospholipid":[14],"binding":[15],"proteins":[16],"expressed":[17],"on,":[18],"or":[19,28,127,161],"bound":[20],"to,":[21],"the":[22,46,49,93,139,168],"surface":[23],"of":[24,43,92,105,138,146,153],"vascular":[25],"endothelial":[26],"cells":[27],"plateles.":[29],"Lupus":[30],"anticoagulants":[31],"(LA),":[32],"anti-cardiolipin":[33],"(aCL)":[34],"anti-beta2glycoprotein":[36],"I":[37],"(a\u03b22GPI)":[38],"among":[41],"subgroups":[42],"aPLAs.":[44],"In":[45,130],"healthy":[47,120],"child,":[48],"aPLAs":[50,114,132],"usually":[52],"transient":[53],"present":[55,135],"in":[56,62,73,118,136],"low":[57],"levels.":[58],"A":[59],"retrospective":[60],"study":[61],"children":[63,94,121],"(median":[64],"age":[65],"5.3":[66],"years)":[67],"found":[68],"to":[69,123,144],"have":[70],"LA":[71],"incidentally":[72],"preoperative":[74],"screening":[75],"showed":[76],"that":[77],"84%":[78],"were":[79,96],"symptom":[80],"free,":[81],"10%":[82],"had":[83,88],"bleeding":[84],"symptoms,":[85],"5%":[87],"thrombotic":[89],"events.":[90],"None":[91],"who":[95],"initially":[97],"symptom-free":[98],"developed":[99],"thrombosis":[100,160],"over":[101],"a":[102],"median":[103],"follow-up":[104],"2.9":[106],"years,":[107],"nor":[108],"did":[109],"they":[110],"develop":[111],"autoimmune":[112],"disease.":[113],"can":[115,133],"be":[116,134],"positive":[117],"otherwise":[119],"secondary":[122],"vaccinations,":[124],"drug":[125],"use,":[126],"previous":[128],"infections.":[129],"adults,":[131],"8%-10%":[137],"normal":[140],"population":[141],"up":[143],"40%":[145],"patients":[147],"with":[148,159],"SLE.":[149],"clinical":[151],"significance":[152],"these":[154],"is":[156],"their":[157],"association":[158,166],"recurrent":[162],"fetal":[163],"loss.":[164],"This":[165],"constitutes":[167],"antiphospholipid":[169],"syndrome":[170],"(APS).":[171]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2021-04-13T00:00:00"}